510 related articles for article (PubMed ID: 26371518)
1. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.
Pareek A; Chandurkar N; Thulaseedharan NK; Legha R; Agarwal M; Mathur SL; Salkar HR; Pednekar S; Pai V; Sriram U; Khyalappa R; Parmar M; Agrawal N; Dhruv U; Saxena S
Curr Med Res Opin; 2015 Nov; 31(11):2105-17. PubMed ID: 26371518
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
4. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
[TBL] [Abstract][Full Text] [Related]
7. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
[TBL] [Abstract][Full Text] [Related]
10. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
Ray KK; Leiter LA; Müller-Wieland D; Cariou B; Colhoun HM; Henry RR; Tinahones FJ; Bujas-Bobanovic M; Domenger C; Letierce A; Samuel R; Del Prato S
Diabetes Obes Metab; 2018 Jun; 20(6):1479-1489. PubMed ID: 29436756
[TBL] [Abstract][Full Text] [Related]
11. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
Rosenson RS; Otvos JD; Hsia J
Diabetes Care; 2009 Jun; 32(6):1087-91. PubMed ID: 19265025
[TBL] [Abstract][Full Text] [Related]
14. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
15. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).
Bardini G; Giorda CB; Pontiroli AE; Le Grazie C; Rotella CM
Cardiovasc Diabetol; 2010 May; 9():20. PubMed ID: 20492655
[TBL] [Abstract][Full Text] [Related]
17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Goldberg AC; Bays HE; Ballantyne CM; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Am J Cardiol; 2009 Feb; 103(4):515-22. PubMed ID: 19195513
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Jun JE; Jeong IK; Yu JM; Kim SR; Lee IK; Han KA; Choi SH; Kim SK; Park HK; Mok JO; Lee YH; Kwon HS; Kim SH; Kang HC; Lee SA; Lee CB; Choi KM; Her SH; Shin WY; Shin MS; Ahn HS; Kang SH; Cho JM; Jo SH; Cha TJ; Kim SY; Won KH; Kim DB; Lee JH; Lee MK
Diabetes Metab J; 2020 Feb; 44(1):78-90. PubMed ID: 31237134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
